the canadian cancer society awards for excellence in cancer research recognize individuals who have made, and are making, valuable contributions to the cancer research ecosystem in canada. recipients are leaders in their fields who exemplify excellence in science and outstanding service to the scientific community. posthumous nominations are not eligible. winners will be recognized and will receive a personalized glass plaque commemorating their award. each award also comes with a $20,000 contribution to the recipient’s research program.

if you are interested in being nominated for this award, please contact dr. batia stolar, associate vice-president, research and graduate studies, at  bstolar@lakeheadu.ca

the goal of the exploration stream is to inspire high-risk, high-reward and interdisciplinary research.

exploration grants support research that pushes boundaries into exciting new areas. researchers are encouraged to think “outside of the box,” undertake research that would defy current paradigms, and bring disciplines together in unexpected ways and from bold, innovative perspectives. with the exploration stream, there is recognition that innovation often carries risk; proposals for high-risk research projects that have the potential to deliver game-changing impacts are strongly encouraged.

exploration stream grants support projects that:

• bring disciplines together beyond traditional disciplinary or common interdisciplinary approaches;
• propose to explore something new, which might fail; and
• have the potential for significant impact.

exploration grants support research with a range of impacts—economic, scientific, artistic, cultural, social, technological, environmental or health-related. this list is not exhaustive; other types of impacts are also recognized. diversity of perspectives is important, and the fund encourages research proposals led from any discipline, from those in the social sciences and humanities, to health, the natural sciences and engineering.

to better promote ground-breaking and interdisciplinary research, the new frontiers in research fund (nfrf) has a mandate to explore innovative merit review processes, and the flexibility for competition parameters and processes to evolve from one competition to the next.

the fy22 crrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

the fy22 crrp will solicit research applications addressing at least one of the focus areas described below.  the focus areas broadly describe current needs to ensure readiness for delivering front-line care in combat situations and for delivering medical damage control capability, assets, and lifesaving interventions to address the emerging needs of the warfighter and service medics during prolonged and en route care in austere and combat environments, including the acute and early management of combat-related trauma at the point of injury. 

applications submitted to the fy22 crrp must address one or more of the following focus areas:

• solutions to enhance warfighter readiness, such as solutions to address:

○       sleep disorders

○       myalgic encephalomyelitis/chronic fatigue syndrome

○       service-related post-traumatic arthritis

○       eating disorders

○       sarcoidosis

○       valley fever

○       complementary health measures to accelerate return to duty

○       regenerative medicine

• ·        solutions to enhance combat care delivery throughout the far-forward environment, such as:

○       telemedicine solutions that enable medical capabilities at far-forward battlespace locations worldwide

○       medical simulation technology that support sustainment of critical skills and medical decision-making

○       blood products, including freeze-dried plasma and platelets

○       ruggedized oxygen generation systems for medical use

○       solutions for the assessment of mild traumatic brain injury, to include portable and hand-held detection devices

○       extracorporeal life support

○       initial treatment and transport of patients with highly transmissible infectious disease

• ·        wound care solutions for complex trauma and tissue regeneration that span the operational medical care continuum or roles of care (e.g., acute through chronic care), such as:

○       multi-modal wound care solutions that provide a combination of hemostasis, wound healing, infection prevention, and/or analgesia

○       repair and restoration of genitourinary injury and tissue damage

the areas of encouragement were identified as capability and knowledge gaps that are of high priority and programmatic relevance and can be found appended to the fy22 funding opportunity announcement.  investigators are strongly encouraged to propose research ideas that specifically address one of the fy22 areas of encouragement within each focus area (if applicable).

funding opportunities-fy22 combat readiness-medical research program, congressionally directed medical research programs (cdmrp) (army.mil)

rapid development and translational research award (rdtra) – preproposal due june 23, 2022

extramural and intramural applicants

independent investigators at all academic levels (or equivalent)

• ·     submission of a preproposal is required; application submission is by invitation only.
• ·     supports high-impact research that will accelerate the movement of promising ideas into clinical applications, including healthcare products, technologies, and/or practice guidelines. 
• ·     proposed research must have the potential for rapid development and translation of applicable advances for improving medical readiness, mitigating fatalities, optimally treating life-threatening injuries, and promoting positive long-term outcomes for military health and medicine, as well as the general public. 
• ·      supports preclinical research, clinical research, and small-scale clinical trials (e.g., first in human, phase 1/1b).  fundamental basic research and phase 2/3 clinical trials are not supported under this funding opportunity.
• ·      proposed research must address at least one of the fy22 crrp focus areas.
  • ·     different funding options are available.  applicants may apply for either the rdtra, or the rdtra with option.  it is the responsibility of the principal investigator to select the funding option that is most appropriate for the research proposed.

o  for applications proposing an rdtra with option, each phase of research must be a distinct research effort with non-overlapping period of performance, research outcomes/milestones, and budget.  research products from the first phase of performance shall be leveraged in the subsequent option phase.

o    exercise of the option is contingent on the availability of sufficient future congressional appropriations to the crrp, alignment of the proposed research during the option to that fiscal year’s congressional language, and acceptable performance by the recipients.

rdtra:

• ·    maximum funding of $2,200,000 for total costs (to include direct and indirect costs).
• ·    maximum period of performance is 2 years.

rdtra with option:

• ·    maximum funding of $2,200,000 (rdtra) and 1,000,000 (option) for total costs (to include direct and indirect costs).
• ·    maximum period of performance is 2 years for the first phase of performance of the rdtra and 1 year for the option.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the crrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca.

the fy22 bmfrp funding opportunity announcements for the following award mechanisms will be posted on the grants.gov website.  . 

applications submitted to the fy22 bmfrp must address one or more of the following focus areas:

•             understand the causes and progression of bmf diseases

•             find effective bmf treatments and cures

funding opportunities-fy22 bone marrow failure research program, congressionally directed medical research programs (cdmrp) (army.mil)

idea development award – preproposal due june 29, 2022

established investigator: independent investigators at or above the level of associate professor (or equivalent) or an assistant professor (or equivalent) with 10 years or more from their first faculty appointment (or equivalent) by the application submission deadline.

early career investigators: independent investigators at the level of assistant professor (or equivalent), and within 10 years from their first faculty appointment (or equivalent) by the application submission deadline.

•             supports innovative ideas and high-impact approaches based on scientifically sound evidence in order to move toward the vision to understand and cure bone marrow failure (bmf) diseases.

•             proposed research should have a high probability of revealing new avenues of investigation.

•             research project should include a well–formulated, testable hypothesis and a well-developed and articulated research approach.

•             must address at least one of the fy22 bmfrp ida focus areas.

•             strong bmf research team.

•             may include relevant preliminary data.

•             clinical trials are not allowed.

•             translational potential should be considered and described.

•             pre-application submission is required; application submission is by invitation only.

•             the maximum allowable funding for the entire period of performance is $450,000 for direct costs.

•             indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

•             the maximum period of performance is 3 years.

investigator-initiated research award (iira) – preproposal due june 29, 2022

investigators at or above the level of assistant professor (or equivalent) by the application submission deadline.

two funding levels of intent:

funding level 1: supports studies that further develop ideas, expand upon key discoveries, and have the potential to make significant advances in bmf research, patient care, and/or quality of life. correlative studies to existing clinical trials/studies are encouraged. translational potential should be considered and described.

o             funding level 2: investigational new drug (ind)-enabling efforts the proposed studies should be empirical in nature, product driven, and focused on the accumulation of data to support an ind application to the u.s. food and drug administration.  applicants are required to identify lead bmf therapy candidate(s), and transition plans should be considered and adequately described.

•             emphasis on research approach and impact.

•             strong bmf research team.

•             preliminary data required.

•             clinical trials are not allowed.

•             must address at least one of the fy22 bmfrp iira focus areas.

•             partnering pi option: allows two pis, termed initiating and partnering pis, to collaborate on a single application.

•             pre-application submission is required; application submission is by invitation only

funding level 1:

•             the maximum allowable funding for the entire period of performance is $600,000 for direct costs.

•             indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

•             the maximum period of performance is 3 years.

funding level 2:

•             the maximum allowable funding for the entire period of performance is $800,000 for direct costs.

•             indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

•             the maximum period of performance is 2 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the bmfrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507

help@ebrap.org

please contact jill sherman, international research facilitator, for more information at intl.research@lakeheadu.ca .

the fy22 defense appropriations act provides funding for the multiple sclerosis research program (msrp) to support innovative and impactful research that addresses fundamental issues and gaps in multiple sclerosis (ms).  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 msrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

funding opportunities-fy22 multiple sclerosis research program, congressionally directed medical research programs (cdmrp) (army.mil)

applications submitted to the fy22 msrp must address one of the focus areas relevant to the award mechanism as described in the table below:

early investigator research award updated!!! – letter of intent due august 2, 2022

the principal investigator must:

• possess a doctoral degree (or equivalent) from an accredited organization; and
• have 4 years or less of postdoctoral research experience at the time of application submission (excluding clinical residency or clinical fellowship training); and
• commit at least 50% of the effort toward the proposed project

only postdoctoral fellows are eligible for this award. faculty members and all other non-postdoctoral positions are not eligible to apply

• supports ms-focused research opportunities for individuals in the early stages of their careers
• designated mentor who is an experienced ms researcher
• clinical trials not allowed
• must address at least one of the following focus areas:
• central nervous system regenerative potential in demyelinating conditions
• correlates of disease activity and progression in ms
• biology and measurement of ms symptoms
• factors contributing to or associated with ms etiology, prodrome, onset, and disease course
• maximum funding of$320,000 for total costs
• maximum period of performance is 2 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the msrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca.

the cmhc housing research awards support research teams and recognize activities that are impactful and innovative in canadian housing including:

• housing research
• research training
• knowledge mobilization and outreach

the awards are designed to build on and sustain canada’s research-based knowledge culture across all fields related to housing.

you can be awarded up to $20,000 and recognized for your work you’ve put into fields related to housing in canada. your research can be in the social sciences and humanities, health and technology—the caveat is that your research must tie back to housing across canada.

choose the award that will compliment your research:

• cmhc president’s medal for outstanding housing research (theme: housing and climate change) ($20,000)
• gold roof award for housing research excellence ($10,000)
• gold roof award for knowledge to action ($10,000)
• north star award for northern or remote research (2 or more up to $5,000)

the fy22 defense appropriations act provides funding for the multiple sclerosis research program (msrp) to support innovative and impactful research that addresses fundamental issues and gaps in multiple sclerosis (ms).  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 msrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

funding opportunities-fy22 multiple sclerosis research program, congressionally directed medical research programs (cdmrp) (army.mil)

applications submitted to the fy22 msrp must address one of the focus areas relevant to the award mechanism as described in the table below:

clinical trial award updated!!! – preproposal due june 23, 2022

investigators at or above the level of assistant professor (or equivalent)

•  funding level 1: supports small scale, early-phase, proof-of-principle clinical trials to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this funding level
• funding level 2: supports larger-scale clinical trials at phase 1 or 2 to determine safety or efficacy (benefit clinical or paraclinical outcomes) in relevant patient populations
• funding must support a clinical trial and may not be used for preclinical studies.
• scientific rationale and preliminary data are required.
• must address at least one of the following focus areas:
• ○ promoting repair, neuroprotection, and remyelination in ms
• ○ treatment of ms symptoms
• pre-application submission is required; application submission is by invitation only.
• the fy22 cta offers two funding levels:
• funding level 1
• maximum funding of $1.6m for total costs
• maximum period of performance is 3 years
• funding level 2
• maximum funding of $4.5m for total costs
• maximum period of performance is 4 years

exploration -hypothesis development award updated!!! – preproposal due june 23, 2022

established investigators:  independent investigators at or above the level of assistant professor (or equivalent)

or

new investigators:  independent investigators no more than 5 years from the start of their faculty position (excluding time spent in residency, fellowship, or on family medical leave)

must not have received more than $300,000 in total direct costs for previous or concurrent ms research as a pi of one or more non-mentored, peer-reviewed grant(s)

• supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the ms research field
• preliminary data not required
• clinical trials not allowed
• new investigator option supports applicants early in their faculty appointments
• must address at least one of the following focus areas:

• ·        central nervous system regenerative potential in demyelinating conditions
• ·        correlates of disease activity and progression in ms
• ·        biology and measurement of ms symptoms
• ·        factors contributing to or associated with ms etiology, prodrome, onset, and disease course

• pre-application submission required; application submission by invitation only
• maximum funding of$250,000 for total costs
• maximum period of performance is 2 years

investigator-initiated research award updated!!! – preproposal due june 23, 2022

established investigators:  independent investigators at or above the level of assistant professor (or equivalent)

or

new investigators:  independent investigators no more than 5 years from the start of their faculty position (excluding time spent in residency, fellowship, or on family medical leave)

must not have received more than $300,000 in total direct costs for previous or concurrent ms research as a pi of one or more non-mentored, peer-reviewed grant(s)

• supports highly rigorous, high-impact research with the potential to make an important contribution to ms research and/or patient care
• preliminary data required
• clinical trials not allowed
• must address at least one of the following focus areas:
  • central nervous system regenerative potential in demyelinating conditions
  • correlates of disease activity and progression in ms
  • biology and measurement of ms symptoms
  • factors contributing to or associated with ms etiology, prodrome, onset, and disease course
• pre-application submission required; application submission by invitation only
• maximum funding of $1,000,000 for total costs
• maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the msrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

for more information, please contact jill sherman, international research faciliator, at intl.research@lakeheadu.ca.

the discovery horizons program provides nserc’s entry-point to the tri-agency interdisciplinary peer-review mechanism. it supports discovery research projects that would significantly benefit from being assessed by a tri-agency interdisciplinary peer review committee, and aims to

1. answer nse research questions that are best addressed through interdisciplinary approaches
2. advance nse disciplines through cross fertilization and new ways of thinking about research questions; ideas and frameworks; approaches and methods; platforms, tools and infrastructure; people, partners and trainees
3. provide leading-edge nse training for highly qualified personnel (hqp) in interdisciplinary research environments